Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?

References

• Abdelwahab SI, Sheikh BY, Taha MM, et al. (2013). Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int J Nanomedicine 8:2163–72
   PubMed Web of Science ®Google Scholar
• Accardo A, Salsano G, Morisco A, et al. (2012). Peptide-modified liposomes for selective targeting of bombesin receptors over expressed by cancer cells: a potential theranostic agent. Int J Nanomedicine 7:2007–17
   PubMed Web of Science ®Google Scholar
• Ahn J, Miura Y, Yamada N, et al. (2015). Antibody fragment-conjugated polymeric micelles incorporating platinum drugs for targeted therapy of pancreatic cancer. Biomaterials 39:23–30
   PubMed Web of Science ®Google Scholar
• Akhtar MJ, Ahamed M, Alhadlaq HA, et al. (2014). Targeted anticancer therapy: over expressed receptors and nanotechnology. Clin Chim Acta 436:78–92
   PubMed Web of Science ®Google Scholar
• Armutlu P, Ozdemir ME, Uney-Yuksektepe F, et al. (2008). Classification of drug molecules considering their IC50 values using mixed-integer linear programming based hyper-boxes method. BMC Bioinformatics 9:411
   PubMed Web of Science ®Google Scholar
• Barve A, Jin W, Cheng K. (2014). Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release 187:118–32
   PubMed Web of Science ®Google Scholar
• Carlsson N, Borde A, Wölfel S, et al. (2011). Quantification of protein concentration by the Bradford method in the presence of pharmaceutical polymers. Anal Biochem 411:116–21
   PubMed Web of Science ®Google Scholar
• Chen Y, Yuan L, Zhou L, et al. (2012). Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int J Nanomedicine 7:4581–91
   PubMed Web of Science ®Google Scholar
• Gandhi NS, Tekade RK, Chougule MB. (2014). Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. J Control Release 194C:238–56
   Web of Science ®Google Scholar
• Hadinoto K, Sundaresan A, Cheow WS. (2013). Lipid-polymer hybrid nanoparticles as new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 85:427–43
   PubMed Web of Science ®Google Scholar
• Han Y, Zhang Y, Li D, et al. (2014). Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomedicine 9:4107–16
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, et al. (2010). Effects of particle size and surface charge on cellular uptake and bio distribution of polymeric nanoparticles. Biomaterials 31:3657–66
   PubMed Web of Science ®Google Scholar
• Hejri A, Khosravi A, Gharanjig K, Hejazi M. (2013). Optimisation of the formulation of β-carotene loaded nanostructured lipid carriers prepared by solvent diffusion method. Food Chem 141:117–23
   PubMed Web of Science ®Google Scholar
• Jiang Z, Sun C, Yin Z, et al. (2012). Comparison of two kinds of nanomedicine for targeted gene therapy: premodified or postmodified gene delivery systems. Int J Nanomedicine 7:2019–31
   PubMed Web of Science ®Google Scholar
• Kasongo KW, Jansch M, Müller RH, Walker RB. (2011). Evaluation of the in vitro differential protein adsorption patterns of didanosine-loaded nanostructured lipid carriers (NLCs) for potential targeting to the brain. J Liposome Res 21:245–54
   PubMed Web of Science ®Google Scholar
• Khajavinia A, Varshosaz J, Dehkordi AJ. (2012). Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin. Nanotechnology 23:405101
   PubMed Web of Science ®Google Scholar
• Kolhatkar RB, Kitchens KM, Swaan PW, Ghandehari H. (2007). Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cyto-toxicity while maintaining membrane permeability. Bioconj Chem 18:2054–60
   PubMed Web of Science ®Google Scholar
• Kolishetti N, Dhar S, Valencia PM, et al. (2010). Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A 107:17939–44
   PubMed Web of Science ®Google Scholar
• Kong F, Zhou F, Ge L, et al. (2012). Mannosylated liposomes for targeted gene delivery. Int J Nanomedicine 7:1079–89
   PubMed Web of Science ®Google Scholar
• Kulhari H, Kulhari DP, Singh MK, Sistla R. (2014). Colloidal stability and physicochemical characterization of bombesin conjugated biodegradable nanoparticles. Colloids Surf A Physicochem Eng Asp 443:459–66
   Web of Science ®Google Scholar
• Landesman-Milo D, Goldsmith M, Leviatan Ben-Arye S, et al. (2013). Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett 334:221–7
   PubMed Web of Science ®Google Scholar
• Luan J, Yang X, Chu L, (2014). PEGylated long circulating nanostructured lipid carriers for Amoitone B: preparation, cytotoxicity and intracellular uptake. J Colloid Interface Sci 428:49–56
   PubMed Web of Science ®Google Scholar
• Malzert-Fréon A, Vrignaud S, Saulnier P, et al. (2006). Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent. Int J Pharm 320:157–64
   PubMed Web of Science ®Google Scholar
• Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
   PubMed Web of Science ®Google Scholar
• Nahire R, Haldar MK, Paul S, et al. (2014). Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells. Biomaterials 35:6482–97
   PubMed Web of Science ®Google Scholar
• Negi LM, Talegaonkar S, Jaggi M, et al. (2014). Surface engineered nanostructured lipid carriers for targeting MDR tumor: part I. Synthesis, characterization and in vitro investigation. Colloid Surf B Biointerfaces 123:600–9
   PubMed Web of Science ®Google Scholar
• Ogawara K, Un K, Tanaka K, et al. (2009). In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells. J Control Release 133:4–10
   PubMed Web of Science ®Google Scholar
• Peeters L, Sanders NN, Jones A, et al. (2007). Post-PEGylated lipoplexes are promising vehicles for gene delivery in RPE cells. J Control Release 121:208–17
   PubMed Web of Science ®Google Scholar
• Shahin M, Soudy R, El-Sikhry H, et al. (2013). Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin. Cancer Lett 334:284–92
   PubMed Web of Science ®Google Scholar
• Shao Z, Shao J, Tan B, et al. (2015). Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomedicine 10:1223–33
   PubMed Web of Science ®Google Scholar
• Shariat S, Badiee A, Jalali SA, et al. (2014). P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett 355:54–60
   PubMed Web of Science ®Google Scholar
• Shi F, Yang G, Ren J, et al. (2013). Formulation design, preparation, and in vitro and in vivo characterizations of β-Elemene-loaded nanostructured lipid carriers. Int J Nanomedicine 8:2533–41
   PubMed Web of Science ®Google Scholar
• Taratula O, Kuzmov A, Shah M, et al. (2013). Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 171:349–57
   PubMed Web of Science ®Google Scholar
• Tsouris V, Joo MK, Kim SH, et al. (2014). Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers. Biotechnol Adv 32:1037–50
   PubMed Web of Science ®Google Scholar
• Wang W, Xi M, Duan X, et al. (2015). Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo. Int J Nanomedicine 10:3737–50
   PubMed Web of Science ®Google Scholar
• Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. (2015). Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200:138–57
   PubMed Web of Science ®Google Scholar
• Xu Z, Chen L, Gu W, et al. (2009). The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30:226–32
   PubMed Web of Science ®Google Scholar
• Yang F, Hu J, Yang D, et al. (2009). Pilot study of targeting magnetic carbon nanotubes to lymph nodes. Nanomedicine (Lond) 4:317–30
   PubMed Web of Science ®Google Scholar
• Yang F, Jin C, Jiang Y, et al. (2011). Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. Cancer Treat Rev 37:633–42
   PubMed Web of Science ®Google Scholar
• Yang XY, Li YX, Li M, et al. (2013). Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 334:338–45
   PubMed Web of Science ®Google Scholar
• Yim H, Na K. (2010). Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein over expressing cancer cells. Biomacromolecules 11:2387–93
   PubMed Web of Science ®Google Scholar
• Yim H, Park SJ, Bae YH, Na K. (2013). Biodegradable cationic nanoparticles loaded with an anticancer drug for deep penetration of heterogeneous tumours. Biomaterials 34:7674–82
   PubMed Web of Science ®Google Scholar
• Yu W, Liu C, Liu Y, et al. (2010). Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res 27:1584–96
   PubMed Web of Science ®Google Scholar
• Yu W, Zhang N. (2009). Surface modifcation of nanocarriers for cancer therapy. Curr Nanosci 5:123–34
   Web of Science ®Google Scholar
• Zhang XG, Miao J, Dai YQ, et al. (2008). Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm 361:239–44
   PubMed Web of Science ®Google Scholar
• Zhao YZ, Dai DD, Lu CT, et al. (2013). Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Lett 330:74–83
   PubMed Web of Science ®Google Scholar
• Zucker D, Marcus D, Barenholz Y, Goldblum A. (2009). Liposome drugs’ loading efficiency: a working model based on loading conditions and drug’s physicochemical properties. J Control Release 139:73–80
   PubMed Web of Science ®Google Scholar